Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ACETAZOLAMIDE

1 general benefit · 1 not a benefit

Other products in the same Health Canada class (S01E, S01EC) — coverage varies; not interchangeable

  • Methazolamide (Neptazane): general benefit, Not a benefit
  • Brinzolamide (Azopt): limited Use 171, 172, 387
  • Brimonidine + brinzolamide (Simbrinza): limited Use 466, 393
  • Dorzolamide (Trusopt): limited Use 171, 172, 387
  • Betaxolol (Betoptic S): general benefit
  • Levobunolol (Betagan): general benefit

11 more in the class list below

Acetazolamide · DIN 00545015 · 250mg · tablet

General benefitMarketed · checked 2026-09-18
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Acetazolamide · DIN 00545015 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2011-04-13 · brand ACETAZOLAMIDE · ATC S01EC01 ACETAZOLAMIDE · form Tablet · route Oral · ingredients ACETAZOLAMIDE 250 MG · company Planta dei pharma inc. · schedule Prescription
Check this DIN again · Health Canada product record

Acetazolamide: Formulary list price $0.1414/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1414 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4899 · Verify on the e-Formulary ↗ (DIN 00545015)

Source record
DIN 00545015: Acetazolamide Raw flags: sec3=Y Item: 523600001; group id 608; item number 1569; lccId None; manufacturer id AAP Source form: Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.1414; ministry $0.1414 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00545015 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4899
Interchangeable products
Diamox · DIN 02238072 · not recorded
Shortage status: resolved shortage (ended 2025-04-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00545015
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Diamox · DIN 02238072 · 250mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-12-03 — choose a marketed DIN from the same-category list.Discontinued 2002-12-03 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-12-03 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-12-03 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diamox · DIN 02238072 Manufacturer: Wyeth Pharmaceuticals; listing date 2000-11-30 Health Canada: Cancelled post market since 2002-12-03 · brand DIAMOX TABLETS 250MG · ATC S01EC01 ACETAZOLAMIDE · form Tablet · route Oral · ingredients ACETAZOLAMIDE 250 MG · company Wyeth-ayerst canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Diamox: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61456 · Verify on the e-Formulary ↗ (DIN 02238072)

Source record
DIN 02238072: Diamox Raw flags: notABenefit=Y, sec3=Y Item: 523600001; group id 608; item number 1569; lccId None; manufacturer id WAY Source form: Tab; strength: 250mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238072 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61456
Interchangeable products
Acetazolamide · DIN 00545015 · $0.1414
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02238072
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2002-12-03 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE 52:36 Other Eye, Ear, Nose and Throat Agents

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

BRINZOLAMIDE

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp

BRINZOLAMIDE & BRIMONIDINE TARTRATE

· 1 products · Limited Use, codes 466, 393 · strengths: 1.0% & 0.2% · Oph Susp-10mL Pk

DORZOLAMIDE HCL

· 5 products · Limited Use, codes 171, 172, 387 · strengths: 2% · Oph Sol

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

TIMOLOL MALEATE

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol

BRIMONIDINE TARTRATE & TIMOLOL MALEATE

· 3 products · Limited Use, codes 310, 393 · strengths: 0.2% & 0.5% · Oph Sol-10mL Pk

BRINZOLAMIDE & TIMOLOL MALEATE

· 1 products · Limited Use, codes 310, 393 · strengths: 1% & 0.5% · Oph Susp-5mL Pk

DORZOLAMIDE HCL & TIMOLOL MALEATE

· 11 products · Limited Use, codes 310, 393 · strengths: 2% & 0.5% · Oph Sol, Oph Sol-0.2mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:36 and 20 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS ACETAZOLAMIDE (acetazolamide tablets) is indicated: • To decrease ocular aqueous humor secretion in glaucoma (chronic, simple and secondary types). • For use as an adjunct in the treatment of selected cases of epilepsy. • To alkalinize the urine in selected cases of salicylate overdosage. 1.1 Pediatrics Pediatrics: No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics: No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00080474.PDF PM date: MAY 7, 2025 Source product: ACETAZOLAMIDE; DIN 00545015; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Diamox: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026